JP2015528454A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528454A5
JP2015528454A5 JP2015529009A JP2015529009A JP2015528454A5 JP 2015528454 A5 JP2015528454 A5 JP 2015528454A5 JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015528454 A5 JP2015528454 A5 JP 2015528454A5
Authority
JP
Japan
Prior art keywords
vegf antagonist
medicament
administered
antibody
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015529009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067846 external-priority patent/WO2014033184A1/en
Publication of JP2015528454A publication Critical patent/JP2015528454A/ja
Publication of JP2015528454A5 publication Critical patent/JP2015528454A5/ja
Pending legal-status Critical Current

Links

JP2015529009A 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用 Pending JP2015528454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693913P 2012-08-28 2012-08-28
US61/693,913 2012-08-28
PCT/EP2013/067846 WO2014033184A1 (en) 2012-08-28 2013-08-28 Use of a vegf antagonist in treating ocular vascular proliferative diseases

Publications (2)

Publication Number Publication Date
JP2015528454A JP2015528454A (ja) 2015-09-28
JP2015528454A5 true JP2015528454A5 (enExample) 2016-11-24

Family

ID=49083670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529009A Pending JP2015528454A (ja) 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用

Country Status (4)

Country Link
US (1) US20150297675A1 (enExample)
EP (1) EP2890389A1 (enExample)
JP (1) JP2015528454A (enExample)
WO (1) WO2014033184A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
EP3010526A1 (en) * 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US20180326126A1 (en) * 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
CN108697772B (zh) 2015-12-30 2022-06-24 马歇尔大学科研协会 用于治疗视网膜病的组合物和方法
BR112018013407A2 (en) * 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019099965A1 (en) * 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
AU2019235577B2 (en) * 2018-03-16 2021-09-30 Novartis Ag Methods for treating ocular diseases
KR102038008B1 (ko) * 2018-04-03 2019-10-29 주식회사 루트로닉 안과용 치료장치 및 이의 제어방법
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
CN114423432A (zh) * 2019-09-13 2022-04-29 奥尔德拉医疗公司 甲氨蝶呤的眼用制剂
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20230023727A (ko) 2020-06-11 2023-02-17 제넨테크, 인크. 나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법
WO2023019216A2 (en) * 2021-08-13 2023-02-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating ischemic eye disease
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110014661A (ko) * 2002-02-07 2011-02-11 노보자임스 바이오파마 디케이 에이/에스 알부민-융합 쿠니츠 도메인 펩타이드
US7399612B2 (en) * 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
AU2009269149B2 (en) * 2008-06-30 2016-03-17 Mesoblast, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
EP2358746B1 (en) * 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
US20120076787A1 (en) * 2009-05-28 2012-03-29 Peter Adamson Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
EP2671589A4 (en) * 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY

Similar Documents

Publication Publication Date Title
JP2015528454A5 (enExample)
JP2012525415A5 (enExample)
JP2016528202A5 (enExample)
KR102373289B1 (ko) 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도
WO2014033184A1 (en) Use of a vegf antagonist in treating ocular vascular proliferative diseases
JP2014532072A5 (enExample)
ME00591B (me) Upotreba dii4 antagonista kod ishemijske povrede ili vaskularne insuficijencije
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2017537105A5 (enExample)
JP5557408B1 (ja) 眼底疾患治療剤
JP2019510078A5 (enExample)
JP2017525769A5 (enExample)
CN114306575A (zh) 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
Tomomatsu et al. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
JP2017523974A5 (enExample)
JP2016516761A5 (enExample)
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
KR20160013026A (ko) 폴립양 맥락막 혈관병증의 치료
Khan et al. Interferon associated retinopathy
SHARM et al. Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema
Tataru et al. Evaluation of the efficacy and safety of intravitreal bevacizumab for macular edema related to retinal vein occlusion
WO2014055054A1 (ru) Применение 1-адамантилетилокси-з-морфолино - 2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
Mahar et al. Visual Outcome Following Intra-vitreal Bevacizumab Injection in Neovascular Age-related Macular Degeneration
Flores et al. Photodynamic Therapy 16